Our finding reveals a critical role of CCL-2 and IL-6 in obesity-associated CNS inflammation and that may be potential therapeutic targets for prevention and treatment of obesity-related MS. This evidence concerns the gene IL6 and obesity due to melanocortin 4 receptor deficiency.